The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg negative and anti-HBc positive), in order to prevent reverse seroconversion. Moreover it is suggested a strict adherence to criteria of allocation based on the virological characteristics of both recipients and donors in the general setting of transplants and in liver transplantation the universal prophylaxis with nucleos(t)ides analogues (frequently combined with specific anti-HBV immunoglobulins) in HBsAg positive candidates and in HBsAg negative recipients of anti-HBc positive grafts.
Prophylaxis and treatment of hepatitis B in immunocompromised patients / A. Marzano, E. Angelucci, P. Andreone, M. Brunetto, R. Bruno, P. Burra, P. Caraceni, B. Daniele, V. Di Marco, F. Fabrizi, S. Fagiuoli, P. Grossi, P. Lampertico, R. Meliconi, A. Mangia, M. Puoti, G. Raimondo, A. Smedile, the Italian Association for the Study of the Liver. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 39:5(2007), pp. 397-408.
|Titolo:||Prophylaxis and treatment of hepatitis B in immunocompromised patients|
|Settore Scientifico Disciplinare:||Settore MED/12 - Gastroenterologia|
|Data di pubblicazione:||2007|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.dld.2006.12.017|
|Appare nelle tipologie:||01 - Articolo su periodico|